About the book
Ovarian cancer (OC) is a heterogeneous disease composed of multiple distinct molecular and clinical subtypes. Women with OC, in particular high grade serous ovarian cancer (HGSOC), face a formidable challenge as fatal resistance to therapies commonly occurs within a few years of diagnosis. Improvement in our ability to target the underlying drivers and vulnerabilities of HGSOC is essential to develop effective treatments for women battling this disease. Despite a decline in age-adjusted incidence and cancer death for OC over the last 2 decades, these advancements and progress are less impressive compared to the breast, colorectal and prostate cancer outcomes. OC is one of only four cancer types that has a smaller decline in age-adjusted death rate compared to age-adjusted incidence rate. As the death rate has not reduced by more than the incidence rate, this suggests that the improvements and advancements in OC screening and treatment have only a modest impact in lowering OC death rate. To develop more effective treatments for HGSOC, an in-depth understanding of the early genetic events in HGSOC tumorigenesis is crucial.
This book will intend to provide the reader with a comprehensive overview of the genomic landscape of ovarian cancer and tumorigenesis, challenges in managing this cancer as well as an in-depth update in novel therapeutic approaches and pre-clinical models. The book will also address major key issues in ovarian cancer survivorship.